Miriam Merad at ARDD2025: Targeting inflammaging to enhance health span

Miriam Merad at ARDD2025: Targeting inflammaging to enhance health span

by Miriam Merad

Life & Natural Systems Medicine & Health MFKHHuman growth and developmentMFKH3Maturation and ageing
🎙 Miriam Merad 👥 9K 📅 January 21, 2026 ⏱ 19 min 👁 252 📄 original study 🧭 2026-08-16
Available in: English (current) Français

Keywords

inflammagingmacrophagespermidineIL-1aging

Summary

Miriam Merad presents her research on the role of macrophages in inflammaging and aging. She distinguishes between tissue-resident macrophages, which are protective and decline with age, and monocyte-derived macrophages, which accumulate and drive inflammation. Her lab identified that polyamine synthesis, particularly spermidine, declines in aged macrophages and hematopoietic stem cells, leading to loss of protective cells and myeloid bias. Supplementing spermidine in mice restored tissue-resident macrophages and improved infection response. She also shows that an aged immune system accelerates tumor progression, driven by IL-1 production from myeloid cells, and that blocking IL-1 reduces tumor growth. She discusses a clinical trial using high-dose spermidine and plans for an FDA-approved inflammaging diagnostic test to guide immunoprevention, particularly for lung cancer. She emphasizes targeting the inflammasome upstream rather than IL-1 receptor to minimize side effects.

132 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides valuable insights into the role of macrophages in aging and presents a compelling hypothesis that targeting inflammaging can enhance health span. The argumentation is solid, supported by data from animal models and human studies, including a large clinical trial (CANTOS) showing IL-1β blockade reduces lung cancer incidence. The speaker acknowledges limitations and discusses ongoing trials, adding credibility. However, some conclusions are based on unpublished data and the translational relevance remains to be confirmed.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor, with references to published studies and ongoing collaborations. The speaker cites specific studies, such as those by Dixit and Swanton, and mentions the CANTOS trial. The title accurately reflects the content. The talk is a conference presentation, so sources are not formally cited, but the speaker’s reputation and the context of the ARDD meeting lend credibility. The adequacy between title and content is high.

160 words

Title / Content Match

The title accurately reflects the content, focusing on targeting inflammaging to enhance health span.

Quality & Reliability

8/10

Presentation of original research by a leading immunologist, with data from published studies and ongoing clinical trials. However, the talk is a conference presentation, not peer-reviewed, and some claims are based on unpublished or preliminary data.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • CANTOS trial — Referenced as a Novartis trial showing IL-1β blockade reduces lung cancer incidence.
  • Swanton et al. (New England Journal) — Referenced for the concept of second hit in cancer initiation.

Concurring Sources

  • CANTOS trial — Supports the role of IL-1β in cancer prevention.

Contribution & Novelties

The talk presents novel findings on the role of spermidine in maintaining tissue-resident macrophages and the potential of IL-1 blockade for cancer prevention. It integrates multiple lines of evidence to propose a comprehensive approach to target inflammaging.

Pour aller plus loin :

  • Inflammaging — Overview of the concept.
  • Spermidine and autophagy — Study on spermidine’s role in autophagy and longevity.
  • CANTOS trial — Original publication of the CANTOS trial.

69 words

Radar Profile

The radar profile shows high scores in information quantity, quality, technical level, and reliability, indicating a well-rounded and credible presentation.

Reliability 8/10